Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn Sells 2,422 Shares

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,422 shares of the stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $50.17, for a total value of $121,511.74. Following the completion of the transaction, the chief operating officer now owns 272,044 shares of the company’s stock, valued at $13,648,447.48. The trade was a 0.88 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Patrick John Finn also recently made the following trade(s):

• On Friday, January 3rd, Patrick John Finn sold 229 shares of Twist Bioscience stock. The shares were sold at an average price of $45.59, for a total value of $10,440.11.
• On Monday, November 11th, Patrick John Finn sold 10,340 shares of Twist Bioscience stock. The shares were sold at an average price of $48.00, for a total value of $496,320.00.
• On Wednesday, November 6th, Patrick John Finn sold 6,239 shares of Twist Bioscience stock. The shares were sold at an average price of $44.60, for a total value of $278,259.40.
• On Monday, November 4th, Patrick John Finn sold 2,681 shares of Twist Bioscience stock. The shares were sold at an average price of $41.56, for a total value of $111,422.36.

Twist Bioscience Stock Down 3.4 %

TWST stock traded down $1.84 during trading on Monday, hitting $52.23. The company had a trading volume of 580,062 shares, compared to its average volume of 722,758. The firm has a market cap of $3.10 billion, a PE ratio of -14.51 and a beta of 1.85. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The firm has a 50-day moving average price of $47.41 and a 200-day moving average price of $46.37.

Hedge Funds Weigh In On Twist Bioscience

Several institutional investors have recently added to or reduced their stakes in TWST. Wilmington Savings Fund Society FSB acquired a new position in Twist Bioscience during the 3rd quarter worth approximately $34,000. Signaturefd LLC increased its position in Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares during the period. Beaird Harris Wealth Management LLC acquired a new position in Twist Bioscience during the 3rd quarter worth approximately $95,000. Mirae Asset Global Investments Co. Ltd. increased its position in Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock worth $98,000 after purchasing an additional 381 shares during the period. Finally, KBC Group NV increased its position in Twist Bioscience by 71.4% during the 4th quarter. KBC Group NV now owns 2,942 shares of the company’s stock worth $137,000 after purchasing an additional 1,226 shares during the period.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on TWST shares. Barclays decreased their target price on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. Wolfe Research initiated coverage on Twist Bioscience in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target for the company. TD Cowen reaffirmed a “buy” rating and set a $58.00 price target on shares of Twist Bioscience in a report on Tuesday, November 26th. Robert W. Baird lifted their price target on Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a report on Tuesday, November 19th. Finally, Evercore ISI lifted their price target on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $51.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.